Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Characterization of the immune impact of daratumumab by mass cytometry in multiple myeloma

Gareth Morgan • 10 Dec 2018
ASH 2018
Multiple Myeloma Daratumumab

Immune alterations in multiple myeloma (MM) involve several cell types, and so mass cytometry can be utilized to study a diverse set of single cells simultaneously. Here, Gareth Morgan, MD, PhD, FRCP, FRCPath, of the UAMS Myeloma Institute, Little Rock, AR, discusses the immune system profiling of MM using CyTOF mass spectrometry, the new platform that couples mass spectrometry with single-cell flow cytometry, allowing the observation of significant changes to the immune status post-daratumumab (DARA) treatment.

More from Gareth Morgan

2:19
How cutting-edge research is changing outcomes in myeloma and the need for novel endpoints in trials
Gareth Morgan • 10 Dec 2023
1:48
Investigating the non-coding myeloma genome
Gareth Morgan • 10 Dec 2023
1:29
Structural variation is a key driver of relapse and aggressive clinical behavior in multiple myeloma
Gareth Morgan • 10 Dec 2023
1:46
Personalizing treatment in multiple myeloma: approaching patients with t(4;14) and t(11;14)
Gareth Morgan • 29 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals